Share Name Share Symbol Market Type Share ISIN Share Description
BTG LSE:BTG London Ordinary Share GB0001001592 ORD 10P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -7.00p -1.09% 635.00p 635.00p 635.50p 637.00p 628.00p 633.50p 211,627 16:18:28
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 447.5 57.5 15.8 40.2 2,432.00

BTG (BTG) Latest News

More BTG News
BTG Takeover Rumours

BTG (BTG) Share Charts

1 Year BTG Chart

1 Year BTG Chart

1 Month BTG Chart

1 Month BTG Chart

Intraday BTG Chart

Intraday BTG Chart

BTG (BTG) Discussions and Chat

BTG Forums and Chat

Date Time Title Posts
26/9/201616:11BTG4,113
12/11/201308:46BTG down the tube6
09/3/201207:16Bright Things3
10/9/200420:24Varisolve hits the FDA buffer's6

Add a New Thread

BTG (BTG) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
16:18:18635.00744.45AT
16:17:30635.0064406.40AT
16:16:16635.00100635.00AT
16:15:51635.5025158.88AT
16:15:51635.504402,796.20AT
View all BTG trades in real-time

BTG (BTG) Top Chat Posts

DateSubject
27/9/2016
09:20
BTG Daily Update: BTG is listed in the Support Services sector of the London Stock Exchange with ticker BTG. The last closing price for BTG was 642p.
BTG has a 4 week average price of 620.35p and a 12 week average price of 646.06p.
The 1 year high share price is 739.50p while the 1 year low share price is currently 504p.
There are currently 382,991,577 shares in issue and the average daily traded volume is 637,493 shares. The market capitalisation of BTG is £2,431,996,513.95.
07/4/2016
00:54
bookish: Directors Talk Broker Ratings » BTG plc 20.3% Potential Upside Indicated by Deutsche Bank broker ratings BTG plc 20.3% Potential Upside Indicated by Deutsche Bank Posted by: Katherine Hargreaves 6th April 2016 BTG plc using EPIC/TICKER code LON:BTG had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 755 GBX on its stock. This now indicates the analyst believes there is a possible upside of 20.3% from today’s opening price of 627.5 GBX. Over the last 30 and 90 trading days the company share price has decreased 1 points and decreased 12.5 points respectively. BTG plc LON:BTG has a 50 day moving average of 614.79 GBX and a 200 day moving average of 626.01 GBX. The 52 week high for the stock is 806.9 GBX while the year low stock price is currently 504 GBX. There are currently 382,991,653 shares in issue with the average daily volume traded being 387,423. Market capitalisation for LON:BTG is £2,397,527,748 GBP.
08/1/2016
10:18
market sniper3: BTG plc 32.8% Potential Upside Indicated by Jefferies International Posted by: Ruth Bannister 7th January 2016 BTG plc with EPIC/TICKER LON:BTG had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ today by analysts at Jefferies International. BTG plc are listed in the Health Care sector within UK Main Market. Jefferies International have set their target price at 850 GBX on its stock. This is indicating the analyst believes there is a potential upside of 32.8% from today’s opening price of 640 GBX. Over the last 30 and 90 trading days the company share price has increased 35 points and decreased 0.5 points respectively. BTG plc LON:BTG has a 50 day moving average of 617.94 GBX and a 200 day moving average of 661.57 GBX. The 1 year high for the share price is 835.87 GBX while the year low share price is currently 504 GBX. There are currently 384,412,303 shares in issue with the average daily volume traded being 401,732. Market capitalisation for LON:BTG is £2,448,706,370 GBP. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.
15/12/2015
10:18
market sniper3: BTG plc 17.8% Potential Upside Indicated by Deutsche Bank Posted by: Amilia Stone 15th December 2015 BTG plc with EPIC/TICKER LON:BTG has had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set their target price at 755 GBX on its stock. This would imply the analyst believes there is now a potential upside of 17.8% from the opening price of 641 GBX. Over the last 30 and 90 trading days the company share price has increased 95.5 points and decreased 3 points respectively. BTG plc LON:BTG has a 50 day moving average of 584.88 GBX and the 200 Day Moving Average price is recorded at 669.43 GBX. The 1 year high share price is 835.87 GBX while the year low share price is currently 504 GBX. There are currently 382,957,017 shares in issue with the average daily volume traded being 585,096. Market capitalisation for LON:BTG is £2,454,754,479 GBP. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.
14/12/2015
15:06
market sniper3: BTG plc 19.5% Potential Upside Indicated by Deutsche Bank Posted by: Ruth Bannister 14th December 2015 BTG plc with EPIC/TICKER LON:BTG had its stock rating noted as ‘Reiterates217; with the recommendation being set at ‘BUY’ this morning by analysts at Deutsche Bank. BTG plc are listed in the Health Care sector within UK Main Market. Deutsche Bank have set a target price of 755 GBX on its stock. This indicates the analyst now believes there is a potential upside of 19.5% from today’s opening price of 632 GBX. Over the last 30 and 90 trading days the company share price has increased 85 points and decreased 10.5 points respectively. BTG plc LON:BTG has a 50 day moving average of 585.37 GBX and a 200 Day Moving Average share price is recorded at 670.05 GBX. The 52 week high for the stock is 835.87 GBX while the 52 week low is 504 GBX. There are currently 382,185,498 shares in issue with the average daily volume traded being 585,096. Market capitalisation for LON:BTG is £2,403,258,877 GBP. BTG plc is a specialist healthcare company. The Company operates in three business segments: Interventional Medicine (IM) (oncology, vascular and pulmonology products), Specialty Pharmaceuticals (antidote products) and Licensing (royalties from licensed assets). The Company’s Interventional Medicine segment offers a portfolio of interventional medicine products that are designed to advance the treatment of liver tumors, advanced emphysema, severe blood clots and varicose veins.
13/10/2015
11:54
cyman: well the last sell recommendation to 565 (I think it was) proved to be a huge success and we were all laughing at it when we were basking in the sunshine of 800p. btg share price reactions of the past have often proven themselves to have been huge over-reactions - like when Louise settled her divorce, everyone was accusing her of all manner of sorcery - so hopefully this too was nothing more than an over reaction and we can start to settle back into the 600's whilst we await next years forecasts etc.
21/6/2015
12:08
spyder: Here are my thoughts on what is happening with the BTG share price, for what they are worth. I suggested in posts to this board several times in the last few months, and most recently at around the time of the results, that the BTG share price was approaching very dangerous chart territory. If it failed to rally, then there would be no support for the shares going forward. Unfortunately, I didn’t “put my money where my mouth was”, because subsequent events proved my comments to be correct and the shares have dropped approximately 20% in the last month or so. I’m afraid the news doesn’t get any better, as, again looking at the chart, this share only has one way to go, and it will continue falling. There could be support at £6.00, and again at £5.00, but I won’t be around to see £5.00 tested if that were to happen and I have an opportunity to exit. To those of you who think charts are nonsense and it is all about the fundamentals, I say that the charts have called it absolutely right so far, in spite of broadly unchanged fundamentals. Indeed, looking at BTGs own forecasts, and almost universally those of the analysts, the outlook remains a positive as ever, so why the freefall? And where are the value buyers? The next few weeks will be a classic test of predicting share price by chart vs fundamentals. If the chart wins, we are heading lower, perhaps significantly. If the fundamentals are to be believed, then value investors should pile in before long. My own strategy is to continue holding, because my investment timeframe is 5 to 10 years, so perhaps one day this will be seen as just another pothole on the road to the FTSE 100. HOWEVER, if the shares fall to £5.80 and linger for more than a day or so, I’m out. Unfortunately I have seen too many extremely successful shares tank for no reason given the fundamentals, only to see that the fundamentals turned out to be hot air. The market (and the chart) usually (but not always!) knows best.
30/3/2015
18:47
a1ord53: We Could Be Seeing A Buying Opportunity With Fast-Growers ARM Holdings plc And BTG plc By Motley Fool | Mon, 30th March 2015 - 09:16 Share this Markets go neither up nor down in straight lines. Every so often, rising share prices suffer a market 'correction' that could end up being nothing more than a brief interruption in upward progress. Not every reversal becomes a bear market If a firm's trading fundamentals don't change and the economic environment remains steady, there's every chance that lower share prices add up to nothing more than market jitters. Such share price reversals, as long as they prove to be temporary, could provide a better value buying opportunity as decent, well-performing companies sell for a lower price on the stock market. The 'trick' for us investors is to make sure a firm's underlying prospects haven't changed and that the valuation still makes sense. If those things seem in order, there's no reason to be shy about buying. Indeed, if we don't buy on market dips, when do we buy? Today, let's take a closer look at two companies with strong forecast earnings growth that have seen their share prices fall in the last few days, ARM Holdings (LSE:ARM) and BTG (LSE:BTG). Upbeat outlook On 11 February, chip designer ARM Holdings posted encouraging fourth-quarter results with strong revenue and growth in earnings. Back then, the chief executive said the firm saw strong licence revenue growth all through 2014, driven by market-leading semiconductor companies increasing their commitment to use ARM technology and a broadening range of new customers choosing ARM technology for the first time. The rate of growth for ARM's royalty revenue even increased during the fourth quarter. The top man reckons 2015 will be a year of exciting opportunities and challenges as ARM invests in new products and technologies, and continues to establish itself in competitive new markets. The firm continues to gain market share and, as chips based on ARMv8-A processors and Mali graphics IP start shipping in higher volumes, the outlook for royalty revenues in 2015 and beyond is encouraging, he says. Yet despite such a bright outlook, ARM Holdings' share price still sold off from recent highs around 1200p over the last few days to follow the stumbles of tech shares across the pond in the US. Can so much have changed for ARM's prospects since February, or is this little trip-up a good time for investors to top up? Exceeding expectations As I write, speciality pharmaceuticals company BTG (LSE:BTG) is also down, in excess of 15% from the 828p or so the share price achieved at the beginning of the year. The firm's overall performance during the year to date has been in line with the directors' expectations, they said, back in February with the interim results release. There's been an upgrade along the way with the company targeting full-year revenue in the range £345m-£360m, up from estimates of £330m to £345m. All seems well. BTG is a growing international specialist healthcare company that is developing and commercialising products targeting acute care, cancer and vascular diseases. The pharmaceutical sector has great longer-term fundamentals and clear growth drivers, and BTG occupies a sweet spot within the industry. The company enjoys diversified revenues from sales of self-marketed products and from royalties on partnered products. Forward earnings-growth projections remain robust. Perhaps it's the US economic growth figures spooking the market a little. A cooling in the fourth quarter saw general after-tax corporate profits record a drop as a strong dollar dented the earnings of multinational corporations. Who knows? There's always something to worry about as bull markets usually climb a wall of worry. Kevin Godbold owns shares in ARM Holdings and BTG. The Motley Fool UK has recommended ARM Holdings and BTG. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.
27/3/2015
16:43
a1ord53: It looks like high flight of BTG share price is over .No support chart wise and no news flow.I also not sure what news we will get ? Hopefully good :) Anybody knows how Varethena and Eco Sphere progressing , also nothing heard on beads business and when we will have BTG year results -in April,May or in March ? Thanks a lot in advance for sharing thoughts and info :)
15/8/2014
07:23
spyder: Thanks Bodgit - actually,I thought this was quite good news in that the negative ruling is old news and therefore in the price already, this story gives hope that it might eventually be reconsidered. NICE, for all their intransigence, do eventually review these things. All that said, I don't suppose it make much difference to the BTG share price one way or another. What really matters is how quickly Varithena is moving off the shelves...
04/4/2014
15:06
red ninja: Just for you : 27 Nov 13 Investec Buy 723.00 13 Nov 13 Jefferies International Hold 420.00p Found Numis target as well TG upgraded by Numis 26th November 2013, 09:01 Numis has upgraded its recommendation on BTG [LON:BTG] to 'hold' from 'reduce' after reassessing its investment case following the recent interim results. The broker stated that its previously ultra-cautious stance was based on the potential impact of strong clinical data for Xtandi, the main competitor to the company's Zytiga prostate cancer treatment drug. However, the broker has noted that BTG's shares have been largely unaffected by positive clinical results from Xtandi, released in October, but remains guarded as the full impact may not be clear for the next twelve months. Despite its continued caution, Numis has increased it price target to 444 pence per share from 350 pence. At 8:59am: BTG share price was up 1.6 pence at 460.5 pence
BTG share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:43 V: D:20160927 15:35:16